Literature DB >> 8865409

Exercise and resting pulmonary function in sarcoidosis.

M Karetzky1, M McDonough.   

Abstract

Patients with sarcoidosis frequently complain of exercise intolerance but reports of the value of static tests of pulmonary function in predicting disability have been contradictory. We studied 32 patients with sarcoidosis and dyspnea, correlating x-ray stages, spirometry and lung volume measurements with graded exercise testing. Patients demonstrated a reduction in maximum workload (Wmax) when compared to an age matched group of 7 normal subjects (p < 0.05). While ventilation (VEmax) at Wmax was lower in patients, when adjusted for workload (V/E/watt) there was relative hyperventilation (p < 0.05). Exercise induced arterial desaturation (PaO2 decrease) was significantly related to resting DLCO% predicted (r = 0.74, p < 0.05). When patients were separated into subgroups of > < DLCO 55% predicted, the lower diffusing capacity group had a lower Wmax and greater fall in exercise PaO2. Chest radiograph staging and the vital capacity proved to be poor predictors of exercise capacity though maximum impairment was associated with advanced x-ray changes and greater decreases in vital capacity. In conclusion, the magnitude of functional impairment may vary widely from apparent histopathologic involvement as reflected by chest x-ray and lung volumes. Actual exercise testing is necessary to accurately characterize and quantitate the impairment in patients with sarcoidosis complaining of dyspnea.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8865409

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  4 in total

1.  Spirometry, cardiopulmonary exercise testing and the six-minute walk test results in sarcoidosis patients.

Authors:  Arda Kiani; Alireza Eslaminejad; Mohsen Shafeipour; Fatemeh Razavi; Seyyed Reza Seyyedi; Babak Sharif-Kashani; Habib Emami; Mehrdad Bakhshayesh-Karam; Atefeh Abedini
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

2.  Is there an added value of cardiopulmonary exercise testing in sarcoidosis patients?

Authors:  Rik G J Marcellis; Antoine F Lenssen; Geeuwke J de Vries; Robert P Baughman; Chris P van der Grinten; Johny A Verschakelen; Jolanda De Vries; Marjolein Drent
Journal:  Lung       Date:  2012-11-09       Impact factor: 2.584

3.  Reduction of exercise capacity in sarcoidosis in relation to disease severity.

Authors:  Anastasios Kallianos; Paul Zarogoulidis; Fotini Ampatzoglou; Georgia Trakada; Elias Gialafos; Georgia Pitsiou; Athanasia Pataka; Lemonia Veletza; Konstantinos Zarogoulidis; Wolfgang Hohenforst-Schmidt; Dimitris Petridis; Ioannis Kioumis; Aggeliki Rapti
Journal:  Patient Prefer Adherence       Date:  2015-08-18       Impact factor: 2.711

4.  Do we need exercise tests to detect gas exchange impairment in fibrotic idiopathic interstitial pneumonias?

Authors:  Benoit Wallaert; Lidwine Wemeau-Stervinou; Julia Salleron; Isabelle Tillie-Leblond; Thierry Perez
Journal:  Pulm Med       Date:  2012-07-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.